Raydiant Oximetry
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$2.1m | Series A | ||
N/A | $1.0m | Grant | |
$3.0m | Grant | ||
$5.0m | Series A | ||
* | $7.5m | Series A | |
Total Funding | €22.9m |
Related Content
Recent News about Raydiant Oximetry
EditRaydiant Oximetry is a pioneering medical technology company focused on improving maternal and fetal health during childbirth. The company has developed a non-invasive photonic sensor technology that directly measures fetal oxygen levels, aiming to significantly reduce the rising mortality and morbidity rates among mothers and babies. Raydiant Oximetry operates in the healthcare market, specifically targeting obstetric care providers and hospitals. The business model revolves around the sale and distribution of its innovative sensor technology, which has received FDA Breakthrough designation and is protected by multiple patents. Revenue is generated through the sale of these sensors and potentially through service agreements with healthcare institutions. The company's team comprises doctors, scientists, nurses, and engineers from prestigious institutions such as Massachusetts General Hospital, Harvard, and Boston University, all united by a mission to make childbirth safer and reduce the number of emergency C-sections. The technology is affordably priced to ensure global accessibility while maintaining attractive margins for investors.
Keywords: photonic sensor, fetal oxygen levels, maternal health, childbirth safety, non-invasive technology, FDA Breakthrough, obstetric care, healthcare innovation, emergency C-sections, global accessibility.